ImmuPharma PLC Valuation
| IMM Stock | 3.34 0.06 1.76% |
At this time, the firm appears to be overvalued. ImmuPharma PLC retains a regular Real Value of USD2.73 per share. The prevalent price of the firm is USD3.34. Our model calculates the value of ImmuPharma PLC from evaluating the firm fundamentals such as Return On Equity of -1.11, return on asset of -0.43, and Shares Outstanding of 416.44 M as well as inspecting its technical indicators and probability of bankruptcy.
Price Book 5.2611 | Enterprise Value 14 M | Enterprise Value Ebitda (0.94) | Price Sales 60.7506 | Enterprise Value Revenue 73.6224 |
Overvalued
Today
Please note that ImmuPharma PLC's price fluctuation is out of control at this time. Calculation of the real value of ImmuPharma PLC is based on 3 months time horizon. Increasing ImmuPharma PLC's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the ImmuPharma stock is determined by what a typical buyer is willing to pay for full or partial control of ImmuPharma PLC. Since ImmuPharma PLC is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ImmuPharma Stock. However, ImmuPharma PLC's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.34 | Real 2.73 | Hype 2.67 | Naive 3.32 |
The real value of ImmuPharma Stock, also known as its intrinsic value, is the underlying worth of ImmuPharma PLC Company, which is reflected in its stock price. It is based on ImmuPharma PLC's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of ImmuPharma PLC's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of ImmuPharma PLC helps investors to forecast how ImmuPharma stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ImmuPharma PLC more accurately as focusing exclusively on ImmuPharma PLC's fundamentals will not take into account other important factors: ImmuPharma PLC Cash |
|
ImmuPharma PLC Total Value Analysis
ImmuPharma PLC is currently forecasted to have takeover price of 13.95 M with market capitalization of 13.91 M, debt of 1.67 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the ImmuPharma PLC fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
13.95 M | 13.91 M | 1.67 M |
ImmuPharma PLC Asset Utilization
One of the ways to look at asset utilization of ImmuPharma is to check how much profit was generated for every dollar of assets it reports. ImmuPharma PLC retains a negative application of resources of -0.43 (percent), losing USD0.0043 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of ImmuPharma PLC shows how discouraging it operates for each dollar spent on its resources.ImmuPharma PLC Ownership Allocation
ImmuPharma PLC has a total of 416.44 Million outstanding shares. ImmuPharma PLC secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.ImmuPharma PLC Profitability Analysis
Net Loss for the year was (2.92 M) with loss before overhead, payroll, taxes, and interest of (69.96 K).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates ImmuPharma PLC's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in ImmuPharma PLC and how it compares across the competition.
About ImmuPharma PLC Valuation
The stock valuation mechanism determines ImmuPharma PLC's current worth on a weekly basis. Our valuation model uses a comparative analysis of ImmuPharma PLC. We calculate exposure to ImmuPharma PLC's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ImmuPharma PLC's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -33.8 K | -32.2 K |
Complementary Tools for ImmuPharma Stock analysis
When running ImmuPharma PLC's price analysis, check to measure ImmuPharma PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmuPharma PLC is operating at the current time. Most of ImmuPharma PLC's value examination focuses on studying past and present price action to predict the probability of ImmuPharma PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmuPharma PLC's price. Additionally, you may evaluate how the addition of ImmuPharma PLC to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |